Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of almost 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB FY Consensus Product Sales Estimates (Average)

In € million 2018a 2019e 2020e 2021e  2022e  2023e  2024e
Cimzia 1,446 1,510 1,523 1,527 1,505 1,457 1,401
Vimpat 1,099 1,221 1,326 1,427 1,201 841 689
Neupro 321 333 342 303 245 210 172
Briviact 142 249 311 371 424 477 545
Keppra 790 732 700 642 595 553 501

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2018a 2019e 2020e 2021e 
Net Sales  4,412 4,531  4,722  4,892 
Revenue  4,632 4,743 4,926 5,093
Recurring EBIT 1,105  1,087 1,179 1,299
Recurring EBITDA 1,398  1,349 1,443 1,563
Net Profit  800 803 879 982
Core EPS (€) 4.78  4.73 5.14 5.71

 

UCB FY Consensus Product Sales Estimates (Median)

In € million 2018a 2019e 2020e 2021e  2022e  2023e  2024e
Cimzia 1,446 1,500 1,537 1,520 1,490 1,437 1,379
Vimpat 1,099 1,219 1,325 1,400 1,184 820 726
Neupro 321 329 336 295 240 199 159
Briviact 142 215 287 365 433 493 550
Keppra 790 760 727 660 597 555 503

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2018a 2019e 2020e 2021e 
Net Sales  4,412 4,529 4,752  4,924 
Revenue  4,632 4,725 4,932 5,127
Recurring EBIT 1,105  1,070 1,183 1,292
Recurring EBITDA  1,398 1,333 1,447 1,568
Net Profit  800  782 879 972
Core EPS (€)  4.78 4.68 5.18 5.66

Downloads:
UCB FY 2018 Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)

Last updated: 20 March, 2019



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.